Charcoal, Activated

Drug class: Antineoplastic Agents

Usage of Charcoal, Activated

Poisonings

May be used for treatment (GI decontamination) in most oral poisonings except those involving corrosive agents (e.g., strong acids or alkalis) or substances for which its absorptive capacity is too low to be clinically useful (e.g., iron salts, lithium, boric acid, arsenic, malathion, or organic solvents such as methanol, ethanol, or ethylene glycol).

Most commonly used agent for GI decontamination in poisoned patients; however, routine administration in poisoned patients is not recommended by American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists (AACT/EAPCCT). Controlled studies demonstrating reduced morbidity and mortality generally are lacking. (See General: Poisonings, under Dosage and Administration.)

Hemoperfusion

Hemoperfusion through columns of activated charcoal to remove endogenous or exogenous toxins in uremia, hepatic failure, or acute toxicity associated with overdose of certain drugs.

GI Disorders

Adsorption of intestinal gases in the treatment of flatulence, intestinal distention, and dyspepsia; FDA classified as lacking substantial evidence of efficacy as antiflatulent or digestive aid.

Has been used alone or combined with kaolin in the management of diarrhea, but value has not been established.

Wounds and Ulcers

Has been used in dressings for suppurating wounds or ulcers to decrease odor and promote healing.

Relate drugs

How to use Charcoal, Activated

General

Poisonings

  • Most effective when administered early, preferably within 30–60 minutes of poison ingestion.
  • Multiple-dose regimens may be considered for drugs that undergo enterohepatic or enteroenteric circulation, those with a small volume of distribution, those that are not extensively protein bound, and those with a low endogenous clearance. Also may be considered for life-threatening ingestions of phenobarbital, Carbamazepine, quinine, dapsone, theophylline, paraquat, or Amanita phalloides.
  • Tablets or granules of activated charcoal are less effective than powder and should not be used in the treatment of poisonings.
  • If help from a poison control center (800-222-1222), emergency medical facility (911), or other qualified health professional cannot be obtained quickly by medically unsupervised individuals attempting to manage acute poisoning, follow directions on the container of activated charcoal.

    • Administration

    Oral Administration

    Administer activated charcoal powder orally or via nasogastric or orogastric tube as extemporaneously prepared slurry or suspension or commercially available suspension.

    Continuous nasogastric infusion or division of the total dose into smaller amounts given more frequently may improve tolerance of large doses.

    If an antiemetic is required to successfully administer high dosages, a serotonin type 3 ( 5-HT3) receptor antagonist (e.g., ondansetron) or metoclopramide may be preferred.

    Sorbitol may be administered with single-dose activated charcoal or with first dose of multiple-dose regimen for palatability and laxative action; additional suspending and flavoring agents generally not recommended.

    Reconstitution

    Extemporaneously, mix powder with sufficient tap water (e.g., 20–30 g in at least 240 mL) to form a slurry.

    Dosage

    Pediatric Patients

    Poisonings Oral Single-Dose or Multiple-Dose Regimens for Treatment of Poisoning in Children

    Age

    Single Dose

    Multiple Doses

    Infants up to 1 year of age

    10–25 g or 0.5–1 g/kg

    Children up to 13 years of age

    25–50 g or 0.5–1 g/kg

    10–25 g initially, then 1–2 g/kg every 2–4 hours

    Adolescents ≥13 years of age

    25–100 g

    50–100 g initially, then 12.5 g every hour, 25 g every 2 hours, or 50 g every 4 hours

    Adults

    Poisonings Oral

    Single dose: 25–100 g or 0.5–1 g /kg; for massive ingestion of a highly toxic substance or if limited adsorption of a lethal substance may provide substantial clinical benefit, 1.5–2 g/kg may be given.

    Multiple doses: 50–100 g, then 12.5 g every hour, 25 g every 2 hours, or 50 g every 4 hours. Alternatively, 0.5–1 g/kg every 4–6 hours for lower-risk ingestions and larger doses (e.g., 1–1.5 g/kg per hour) for more serious ingestions (e.g., life-threatening ingestion of extended-release theophylline). Continue multiple-dose therapy until patient recovers or major toxicity resolves.

    GI Disorders Oral

    0.6–5 g as a single dose or 0.975–3.9 g 3 times daily after meals.

    Warnings

    Contraindications

  • Before endoscopy after ingestion of corrosive agents, unless necessary to adsorb another ingested toxin; may obscure endoscopic evaluation of gastroesophageal lesions.
  • Patients with an unprotected airway, a GI tract that is not anatomically intact, and where risk or severity of aspiration may be increased (e.g., hydrocarbon ingestions).
  • Multiple-dose regimen in presence of ileus or bowel obstruction.

    • Warnings/Precautions

    Warnings

    Petroleum Distillates Ingestion

    Do not use for ingestion of petroleum distillates (e.g., gasoline, kerosene); limited efficacy, and toxicity other than aspiration is rare.

    Sorbitol and Cathartics

    Sorbitol, present in many commercial preparations, should be administered only with a single dose of activated charcoal or the first dose of multiple-dose activated charcoal; no more than 1 or 2 doses of sorbitol or another cathartic (if required) should be used in a 24-hour period because of potential for dehydration, hypotension, electrolyte disturbances (e.g., hypernatremia) associated with excessive catharsis.

    If sorbitol is used with an initial dose of activated charcoal, a second cathartic generally should not be administered.

    Use sorbitol with caution in children and geriatric patients; monitor hydration and electrolytes.

    General Precautions

    GI Effects

    May cause vomiting, constipation, diarrhea, and GI obstruction or fecal impaction in dehydrated patients.

    Generally should not be used when decreased peristalsis present (reduced or absent bowel sounds); if risk of GI obstruction, perforation, or hemorrhage exists; if surgery has occurred recently; or if electrolyte imbalance or volume depletion exists.

    Pulmonary Effects

    Aspiration of activated charcoal may lead to more severe complications than aspiration of gastric contents alone. Aspiration from vomiting or misdirected nasogastric catheter has resulted in granulomatous reactions, bronchiolitis obliterans, tissue reaction to suspension agents (sorbitol, povidone), increased lung permeability, and rarely, death.

    Take measures to reduce the risk of aspiration (e.g., placement of a cuffed endotracheal tube in patients with impaired laryngeal reflexes).

    Use of Fixed Combination

    When used in fixed combination with other agents, consider the cautions, precautions, and contraindications associated with the concomitant agents.

    Common Adverse Effects

    Vomiting, diarrhea, constipation, black stools.

    What other drugs will affect Charcoal, Activated

    May decrease absorption of and therapeutic response to other orally administered drugs. Drugs other than those used for GI decontamination or antidotes for ingested toxins should not be given within 2 hours of activated charcoal; if necessary, concomitant drug therapy can be given parenterally.

    Specific Drugs

    Drug

    Interaction

    Comments

    Acetylcysteine, oral

    Adsorption of acetylcysteine in vitro; no substantial decrease in efficacy apparent in human studies

    Ipecac syrup

    Ipecac-induced emesis may interfere with adsorptive efficacy of activated charcoal; decreased emesis with ipecac unlikely

    Ipecac not generally recommended; if ipecac has been used to induce emesis, administer activated charcoal after vomiting has ceased

    Polyethylene glycol and electrolyte solutions

    Potential decreased adsorptive capacity of activated charcoal

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords

    AI Assitant